Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
Regeneron's Libtayo is chugging along in skin cancer. Next stop? First-line lung
Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other “Serious” Illnesses
Leo Pharma Enters Partnership to Develop Topical Treatment for Rare Skin Cancer
How pharma fuses behavioral science and tech for brand marketing
Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and the German biotech company MorphoSys. The deal in which Novartis has agreed to pay €95 million, will transfer the exclusive global development and marketing rights for the atopic dermatitis (eczema) drug to the Swiss … Συνεχίστε να διαβάζετε Novartis buys eczema drug in €95m deal.
Philadelphia PA and Sydney Australia, 7 June 2018 --Medical dermatology companyBotanix Pharmaceuticals Limited(ASX:BOT, "Botanix" or "The Company") is pleased to release a presentation containing supplementary information on the BTX 1204 atopic dermatitis Phase lb study results. Key highlights Study data indicated BTX 1204 was twice as effective over the vehicle with substantial improvement in the … Συνεχίστε να διαβάζετε BTX 1204 Atopic Dermatitis Study Results Presentation.